Skip to main content
. 2024 May 29;14(6):314. doi: 10.3390/metabo14060314

Figure 1.

Figure 1

Role of SPMs in respiratory inflammation and injury. (A) In mouse lung transplantation, Resolvin D1 and its receptor, ALX/FPR2, block both excessive neutrophil diapedesis and swarming, demonstrating RvD1′s efficacy in preventing early neutrophil-mediated tissue damage after lung transplant [7]. (B) In allergic lung inflammation, RvD2 decreases the number of IL-5 producing CD4+ T-cells, ILC2 cells, and neutrophils while regulating the number of eosinophils [24]. (C) In a 2-hit model of sepsis with secondary lung infection, RvD2 promotes host defense and induces antimicrobial activity by decreasing bacterial load and increasing the number of MDSCs, CD8, and CD4 T-cells in the spleen [39,40]. (D) During RSV-induced lung inflammation, the activation of the MaR1-LGR6 axis reduces IL-13 secretion from ILC2 cells and a CD4 T helper while inhibiting FoxP3-expressing Tregs, highlighting the protective role of the MaR1-LGR6 signaling axis and leading to decreased viral burden, pathogen-induced inflammation, and the restoration of airway function [41].